NFA
PCRX icon

Nationwide Fund Advisors’s Pacira BioSciences PCRX Stock Holding History

Nationwide Fund Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100,534
Closed -$3.77M – 1506
2017
Q3 		$3.77M Buy
100,534
+33,734
+51% +$1.36M 0.01% 1149
2017
Q2 		$3.19M Buy
66,800
+10,610
+19% +$492K 0.01% 1228
2017
Q1 		$2.56M Buy
56,190
+33,482
+147% +$1.45M 0.01% 1297
2016
Q4 		$733K Sell
22,708
-1,108
-5% -$37K ﹤0.01% 1952
2016
Q3 		$815K Hold
23,816
– – ﹤0.01% 1907
2016
Q2 		$803K Buy
23,816
+224
+0.9% +$11K ﹤0.01% 1873
2016
Q1 		$1.27M Sell
23,592
-10,474
-31% -$613K 0.01% 1579
2015
Q4 		$2.62M Sell
34,066
-27,044
-44% -$1.53M 0.01% 1237
2015
Q3 		$2.51M Buy
61,110
+37,500
+159% +$2.3M 0.01% 1253
2015
Q2 		$1.67M Sell
23,610
-12,425
-34% -$979K 0.01% 1550
2015
Q1 		$3.2M Sell
36,035
-11,202
-24% -$1.14M 0.01% 1214
2014
Q4 		$4.19M Sell
47,237
-6,109
-11% -$578K 0.02% 1037
2014
Q3 		$5.17M Sell
53,346
-399
-0.7% -$38.8K 0.02% 932
2014
Q2 		$4.94M Buy
53,745
+8,076
+18% +$615K 0.02% 977
2014
Q1 		$3.2M Buy
45,669
+24,346
+114% +$1.66M 0.01% 1097
2013
Q4 		$1.23M Sell
21,323
-604
-3% -$31.8K 0.01% 1757
2013
Q3 		$1.05M Buy
21,927
+4,960
+29% +$181K ﹤0.01% 1822
2013
Q2 		$492K Buy
+16,967
New +$491K ﹤0.01% 2021

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Nationwide Fund Advisors's PCRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 100,534 shares — an estimated $3.77M sold.

Nationwide Fund Advisors first reported a position in PCRX in Q2 2013 and held it in 18 quarters. The position peaked at $5.17M in Q3 2014. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 100,534 Pacira BioSciences shares in Q4 2017, an estimated $3.77M.
  • Nationwide Fund Advisors first reported a position in Pacira BioSciences in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Pacira BioSciences position peaked at $5.17M in Q3 2014.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.